Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the Bishop study.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorResende, Gustavo Gomes-
Autor(es): dc.creatorLage, Ricardo da Cruz-
Autor(es): dc.creatorLobê, Samara de Quadros-
Autor(es): dc.creatorMedeiros, Amanda Fonseca-
Autor(es): dc.creatorSilva, Alessandra Dias Costa e-
Autor(es): dc.creatorSá , Antonio Tolentino Nogueira-
Autor(es): dc.creatorOliveira, Argenil José de Assis-
Autor(es): dc.creatorSousa, Denise-
Autor(es): dc.creatorGuimarães, Henrique Cerqueira-
Autor(es): dc.creatorGomes, Isabella Coelho-
Autor(es): dc.creatorSouza, Renan Pedra de-
Autor(es): dc.creatorAguiar, Renato Santana de-
Autor(es): dc.creatorTunala, Roberto-
Autor(es): dc.creatorForestiero, Francisco José-
Autor(es): dc.creatorBueno Filho, Julio Sílvio de Sousa-
Autor(es): dc.creatorTeixeira, Mauro Martins-
Data de aceite: dc.date.accessioned2025-08-21T15:39:54Z-
Data de disponibilização: dc.date.available2025-08-21T15:39:54Z-
Data de envio: dc.date.issued2025-03-25-
Data de envio: dc.date.issued2021-
Fonte completa do material: dc.identifierhttps://www.repositorio.ufop.br/handle/123456789/20035-
Fonte completa do material: dc.identifierhttps://www.tandfonline.com/doi/pdf/10.1080/23744235.2022.2066171-
Fonte completa do material: dc.identifierhttps://doi.org/10.1080/23744235.2022.2066171-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1021014-
Descrição: dc.descriptionBackground: Patients with severe COVID-19 seem to evolve with a compromised antiviral response and hyperinflamma- tion. Neutrophils are critical players in COVID-19. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction/activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could prevent the deleterious hyperinflammation in COVID-19. Methods: BISHOP was a randomized, open-label, single-centre, phase-II controlled trial. Fifty adult patients hospitalized with PCR-positive Covid-19, were randomized 1:1 to receive 300 mg of secukinumab subcutaneously at day-0 plus standard of care (group A) or standard of care alone (group B). A second dose of 300 mg of secukinumab could be administered on day-7, according to staff judgement. The primary endpoint was ventilator-free days at day-28 (VFD-28). Secondary efficacy and safety outcomes were also explored. Results: An intention-to-treat analysis showed no difference in VFD-28: 23.7 (95%CI 19.6–27.8) in group A vs. 23.8 (19.9–27.6) in group B, p 1⁄4 .62; There was also no difference in hospitalization time, intensive care unit demand and the incidence of circulatory shock, acute kidney injury, fungal or bacterial co-infections. There was no difference in the inci- dence of severe adverse events. Pulmonary thromboembolism occurred only in males and was less frequent in secukinu- mab-treated patients (4.2% vs. 26.2% p 1⁄4 .04). There was one death in each group. Upper airway viral clearance was also similar in both groups. Conclusion: The efficacy of secukinumab in the treatment of Covid19 was not demonstrated. Secukinumab decreased pul- monary embolism in male patients. There was no difference between groups in adverse events and no unexpected events were observed.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectCovid-19-
Palavras-chave: dc.subjectSecukinumab-
Palavras-chave: dc.subjectPulmonary thromboembolism-
Palavras-chave: dc.subjectThromboinflammation-
Título: dc.titleBlockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the Bishop study.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.